Inhibikase Therapeutics, Inc.

IKT

Inhibikase Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $260,500.00, up 111.1% from fiscal 2022.

Quarter to June 2026, against a year earlier

1.50 0.06 +4.17%

Follow IKT

Alert me

Overview

	Jun '26	Mar '26	Dec '25	Sep '25	Older periods
ROE Full definition →	(51.96%)	(40.23%)	(36.05%)	(131.71%)	+8 more TTM periods Free account
ROA Full definition →	(48.04%)	(38.09%)	(34.49%)	(113.51%)
ROIC Full definition →	0.00%	0.00%	0.00%	0.00%
Return on Tangible Assets Full definition →	(39.87%)	(30.61%)	(28.09%)	(66.34%)
Average Days of Receivables Full definition →	—	—	—	—
Free Cash Flow per Share Full definition →	(0.24)	(0.21)	(0.28)	(0.28)
Free Cash Flow Full definition →	(42.61)	(35.74)	(27.80)	(25.63)
Capital Expenditures Full definition →	—	—	(0.01)	(0.01)
Other line items
Cash ROIC Full definition →	(13.64%)	(10.58%)	(7.91%)	(17.06%)
Accounts Payable Turnover Full definition →	0.00	0.00	0.00	0.00
Average Days of Payables Full definition →	0.00	0.00	0.00	0.00
Tax Rate Full definition →	0.00	0.00	0.00	0.00
Research and Development Expense of Revenue Full definition →	0.00%	0.00%	0.00%	0.00%
Selling, General and Administrative Expense of Revenue Full definition →	0.00%	0.00%	0.00%	0.00%
Share Based Compensation of Revenue Full definition →	0.00%	0.00%	0.00%	0.00%
Operating CF/Net income Full definition →	0.70	0.70	0.58	0.54
Depreciation/Fixed assets Full definition →	—	—	0.00	0.00
Capex/Depreciation Full definition →	—	—	(0.22)	(0.20)
Revenue per Share Full definition →	0.00	0.00	0.00	0.00
Operating CF per Share Full definition →	(0.24)	(0.21)	(0.28)	(0.28)
Capex per Share Full definition →	0.00	0.00	0.00	0.00
Capex to Sales Full definition →	—	—	0.00	0.00

Columns are period end dates · fundamentals updated 26 Oct 2026